期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 8, 期 10, 页码 1627-1632出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.8.10.1627
关键词
alicaforsen; antisense oligodeoxyribonucleotides; Crohn's disease; ICAM-1; immunosuppressive agents; inflammatory bowel disease; ISIS 2302; pouchitis; ulcerative colitis
Background: Alicaforsen (ISIS 2302), an antisense to intercellular adhesion molecule-1 (ICAM-1) (CD54), was designed to inhibit ICAM-1 expression. ICAM-1 seems to play a role in cell-mediated inflammation, specifically cell trafficking. For this reason, it may be useful in a variety of immune-mediated diseases, including inflammatory bowel disease. Objective: To evaluate the use of alicaforsen in clinical trials to understand its efficacy and side effects, as well as assess for evidence that may offer insight into disease pathways. Methods: We evaluate all of the available, published trials, with a focus on the prospective, randomized trials. Results/conclusions: Systemic treatment for Crohn's disease has not revealed significant effect. Topical enemas for ulcerative colitis have demonstrated some effect in secondary outcomes, and initial studies in pouchitis are promising. In general, the compound has been well tolerated and safe.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据